@inbook{15876abee3b64a9f8bedb93d0b2fe431,
title = "Hypoglycemia",
abstract = "Hypoglycemia is common in insulin, sulfonylurea, or glinide-treated diabetes where it is typically the result of the interplay of therapeutic insulin excess and compromised physiological and behavioral defenses against falling glucose levels. It is uncommon in the absence of diabetes where it is most commonly caused by drugs including alcohol among many others. Hypoglycemia is suggested by neurogenic (autonomic) and neuroglycopenic symptoms and signs of sympathoadrenal activation. It is confirmed by documentation of a low plasma glucose concentration with resolution of symptoms and signs after the glucose level is raised. In the short term, it is treated with oral carbohydrate, subcutaneous glucagon, or intravenous glucose. In the long term, it is prevented by correction of its original cause.",
keywords = "Autonomic failure, Continuous glucose monitoring, Conventional risk factor, Recurrent hypoglycemia, Severe hypoglycemia",
author = "Cryer, {Philip E.}",
note = "Funding Information: Acknowledgments The author{\textquoteright}s original work cited was supported, in part, by the National Institutes of Health grants R37 DK27085, MO1 RR00036 (now UL1 RR24992), P60 DK20579, and T32 DK07120 and by a fellowship award from the American Diabetes Association. Ms. Janet Dedeke, the author{\textquoteright}s assistant, prepared this manuscript. Publisher Copyright: {\textcopyright} 2021, Springer Nature Switzerland AG.",
year = "2021",
doi = "10.1007/978-3-030-67455-7_3",
language = "English",
series = "Contemporary Endocrinology",
publisher = "Humana Press Inc.",
pages = "27--35",
booktitle = "Contemporary Endocrinology",
}